Victory Capital Management Inc. cut its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 1.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,459 shares of the biotechnology company’s stock after selling 510 shares during the quarter. Victory Capital Management Inc. owned about 0.15% of REGENXBIO worth $918,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Perceptive Advisors LLC increased its holdings in shares of REGENXBIO by 8.9% during the 1st quarter. Perceptive Advisors LLC now owns 1,396,244 shares of the biotechnology company’s stock worth $26,947,000 after acquiring an additional 113,958 shares during the last quarter. Redmile Group LLC acquired a new position in shares of REGENXBIO during the 1st quarter worth approximately $24,494,000. JPMorgan Chase & Co. increased its holdings in shares of REGENXBIO by 17.6% during the 1st quarter. JPMorgan Chase & Co. now owns 1,175,794 shares of the biotechnology company’s stock worth $22,693,000 after acquiring an additional 176,047 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of REGENXBIO by 23.2% during the 1st quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock worth $18,942,000 after acquiring an additional 184,700 shares during the last quarter. Finally, Citadel Advisors LLC increased its holdings in shares of REGENXBIO by 625.1% during the 1st quarter. Citadel Advisors LLC now owns 559,887 shares of the biotechnology company’s stock worth $10,806,000 after acquiring an additional 482,667 shares during the last quarter. 73.23% of the stock is currently owned by institutional investors and hedge funds.

In other REGENXBIO news, Director Donald J. Hayden, Jr. sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $24.95, for a total value of $499,000.00. Following the completion of the sale, the director now directly owns 20,000 shares of the company’s stock, valued at $499,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen Yoo sold 27,342 shares of the firm’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $25.00, for a total value of $683,550.00. Following the completion of the sale, the insider now directly owns 27,342 shares of the company’s stock, valued at $683,550. The disclosure for this sale can be found here. Insiders sold 116,140 shares of company stock valued at $2,766,560 over the last three months. Company insiders own 17.00% of the company’s stock.

REGENXBIO Inc. (RGNX) opened at 28.25 on Friday. REGENXBIO Inc. has a one year low of $13.61 and a one year high of $28.40. The firm’s market capitalization is $872.76 million. The firm has a 50-day moving average price of $26.57 and a 200-day moving average price of $23.37.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. The business had revenue of $6.56 million during the quarter. Analysts expect that REGENXBIO Inc. will post ($2.87) EPS for the current year.

A number of research firms recently weighed in on RGNX. Evercore ISI began coverage on REGENXBIO in a report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 target price on the stock. BidaskClub raised REGENXBIO from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Chardan Capital boosted their target price on REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Zacks Investment Research raised REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Saturday, August 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $37.00.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/16/regenxbio-inc-rgnx-position-decreased-by-victory-capital-management-inc.html.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX).

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Stock Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related stocks with our FREE daily email newsletter.